Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé.
Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize MDP’s initial programs. In exchange, the new biotech will receive milestone payments as the technology progresses.
For its part, Enterome is spinning out its IP and all current programs on microbiome-based diagnostics excluding those with applications in immuno-oncology, where the company is already partnered with Bristol-Myers Squibb. Enterome’s CEO Pierre Belichard will become Chairman, while Nestlé’s Warren Cresswell will be the CEO.
The first program of MDP will focus on Enterome’s MET210 biomarker to diagnose progressive liver diseases such as NAFLD and NASH, one of the hottest medical areas at the moment. Nestlé’s Prometheus Laboratories will also contribute its own biomarkers to the program.
Image via Tsvetkov Maxim / Shutterstock